Why AI’s Biggest Impact in Recruitment Isn’t Patient Finding

Artificial intelligence (AI) has become one of the most discussed opportunities in clinical development and one of the most misunderstood. Nowhere is this more evident than AI in patient recruitment, a domain long constrained by structural inefficiencies, limited patient activation, and an overreliance on traditional funnel-based thinking.

Despite decades of investment, patient recruitment remains the single greatest cause of trial delays. Industry data consistently shows that 80% of trials struggle to meet enrollment timelines. This is not because the sponsors cannot find patients, but because we the systems are not built to activate, support, and retain them. AI in clinical trials has largely focused on operational efficiencies rather than transformative patient-centric models.

A recent expert discussion at the Indegene Digital Summit, featuring Ram Yeleswarapu, Angela Radcliffe, and Craig Lipset, sheds light on how AI can reshape the recruitment paradigm—not through incremental efficiencies, but by rethinking the fundamental assumptions behind engagement, protocol design, real-world data (RWD), and site enablement. The conversation underscores a provocative but crucial shift: AI is not simply a tool for patient finding; it is a catalyst for reengineering the patient recruitment ecosystem.

One of the most persistent misconceptions in clinical operations is the tendency to use automation and applied AI interchangeably. Radcliffe highlighted this distinction succinctly: automation functions like a nervous system - executing predefined tasks like pre-screening workflows or templated outreach. AI behaves more like a brain—recognizing patterns, interpreting nuance, and adapting to complex human behaviour. AI in clinical trials brings true clinical trial innovation into recruitment workflows. Most recruitment processes today are optimized around automation with rule-based pre-screeners, scripted outreach, and static content libraries. These do reduce site burden, but they do not solve the deeper challenge. Patients are complex, and their decision to consider research is shaped by individual belief systems, literacy levels, social context, and emotional readiness. Applied AI in patient recruitment, by contrast, enables:

This is not an incremental shift. It is an epistemic shift where you replace linear workflows with systems that learn, anticipate, and guide.

A recurring theme from both Radcliffe and Lipset is that the industry focuses too heavily on patient "identification." Millions of eligible patients walk past clinical trials every year, not because they cannot be found, but because they are never activated. Finding patients is the simplest part of the equation. EHRs, claims data, registries, and digital phenotyping have made discoverability more robust than ever. The true opportunity lies in patient activation—helping individuals understand, consider, and confidently participate in research.

Patient-centricity and AI can converge to create meaningful change through:

Clinical trials are rarely top-of-mind for patients. They must be introduced, understood, and trusted. AI can be the mechanism that finally bridges that gap. The Untapped Opportunity: Reimagining Protocol Design One of the most transformative applications of AI in the next decade will not be recruitment at all. It will be protocol optimization. Radcliffe notes that AI can now analyze the relationship between visit schedules, procedures, data burden, and patient experience with a level of granularity that humans cannot replicate.

Used together, they build a multi-dimensional model of patient needs, readiness, and burden. Applied AI can then use that model to highlight blind spots, suggest more realistic eligibility criteria, and reframe trial design around real-world patterns of care. AI is not just improving recruitment; it is improving the design of the trial patients are being recruited into.

Traditionally, RWD has been applied narrowly: to verify prevalence, validate feasibility, or refine eligibility criteria. But Radcliffe argued that the industry must go further. RWD should be used to understand patient readiness. This includes:

Health system interactions AI in clinical trials can use these data inputs to determine: Which patients need additional support

This is not about filtering patients out; it is about preparing them to succeed once they are in.

Lipset introduced a critical perspective that patients already have physicians. Most targeted patients are diagnosed, treated, and actively managed. Yet the industry invests disproportionately in direct-to-patient channels—social ads, search campaigns, and digital outreach—often at the expense of physician engagement. This has three consequences:

Lipset calls clinician engagement the industry's "unicorn use case", and AI can finally help unlock it. Through provider-facing AI tools, sponsors can:

This creates a fundamentally different funnel - not pulling patients out of the healthcare system but activating them with the healthcare system.

Addressing Bias and Fairness: Beyond Regulatory Compliance AI systems are often criticized for perpetuating bias, but Radcliffe argued that the largest bias is not algorithmic but systemic. Trials are designed for the 10–12% of Americans who are sufficiently health literate to navigate them independently. The rest are unintentionally excluded by design. Applying AI fairly requires:

Lipset also added an essential dimension: Perception drives trust. Even if an AI model is technically fair, communities historically underrepresented in research may perceive algorithmic decisions as exclusionary, especially when historical control arm data is reused. Building trust requires raising the curtain: showing how data is used, how fairness is monitored, and how patient representation is being actively improved. The Often-Overlooked Domain: AI for Site Enablement Technology intended to "support" sites often increases burden with more systems, more training, more fragmentation. Sites are juggling dozens of protocols, each with its own requirements, systems, and visit schedules. Radcliffe highlights several high-value AI applications for site enablement:

AI can finally make trial conduct easier at the site level - something technology has failed to achieve for decades.

What AI Investment Would Move the Needle Most? When asked to choose a single AI investment that would meaningfully accelerate enrollment:

Lipset: Enable HCP-Driven Referral Pathways AI should strengthen and not circumvent the patient-physician relationship. Clinician-first pathways are the most underutilized opportunity in recruitment.

Radcliffe: AI-Powered Health Literacy and Adaptive Education. The world needs scalable tools that personalize trial education to each patient's literacy, readiness, and context. This would transform conversion rates across every therapeutic area.

AI will move the needle in patient recruitment, but not where many expect. The greatest impact will come from: